{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:55:34Z","timestamp":1775555734869,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T00:00:00Z","timestamp":1775347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T00:00:00Z","timestamp":1775520000000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MH CZ\u2014DRO (UHHK, 00179906)"],"award-info":[{"award-number":["MH CZ\u2014DRO (UHHK, 00179906)"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Univerzita Karlova v Praze","doi-asserted-by":"publisher","award":["COOPERATIO Program, research area ONCO"],"award-info":[{"award-number":["COOPERATIO Program, research area ONCO"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04892-7","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T21:25:08Z","timestamp":1775424308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Durable complete metabolic responses to androgen receptor-targeted therapy in metastatic primary cutaneous apocrine carcinoma: a case report and literature review"],"prefix":"10.1007","volume":"17","author":[{"given":"Jind\u0159ich","family":"Kopeck\u00fd","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Al\u017eebeta","family":"Ko\u0159en\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Priester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Dole\u017eal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Ka\u0161parov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aneta","family":"Kyllarov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,5]]},"reference":[{"issue":"1","key":"4892_CR1","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jaad.2022.04.052","volume":"88","author":"DC Gibbs","year":"2023","unstructured":"Gibbs DC, Yeung H, Blalock TW. Incidence and trends of cutaneous adnexal tumors in the United States in 2000\u20132018: a population-based study. J Am Acad Dermatol. 2023;88(1):226\u20138. https:\/\/doi.org\/10.1016\/j.jaad.2022.04.052.","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"4892_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/jjco\/hyae103","volume":"54","author":"S Tsuruta","year":"2024","unstructured":"Tsuruta S, Ogata D, Namikawa K, Nakano E, Yamazaki N. A review of cutaneous apocrine carcinoma: epidemiology, diagnosis, prognosis, and treatment options. Jpn J Clin Oncol. 2024;54(11):1135\u201340. https:\/\/doi.org\/10.1093\/jjco\/hyae103.","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"4892_CR3","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.humpath.2013.09.007","volume":"45","author":"A Piris","year":"2014","unstructured":"Piris A, Peng Y, Boussahmain C, et al. Cutaneous and mammary apocrine carcinomas have different immunoprofiles. Hum Pathol. 2014;45(2):320\u20136. https:\/\/doi.org\/10.1016\/j.humpath.2013.09.007.","journal-title":"Hum Pathol"},{"issue":"2","key":"4892_CR4","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1097\/00000421-199904000-00005","volume":"22","author":"RS Chamberlain","year":"1999","unstructured":"Chamberlain RS, Huber K, White JC, Travaglino-Parda R. Apocrine gland carcinoma of the axilla: review of the literature and recommendations for treatment. Am J Clin Oncol. 1999;22(2):131\u20135. https:\/\/doi.org\/10.1097\/00000421-199904000-00005.","journal-title":"Am J Clin Oncol"},{"issue":"4","key":"4892_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1007\/s10147-013-0594-x","volume":"19","author":"D Ogata","year":"2014","unstructured":"Ogata D, Kiyohara Y, Yoshikawa S, Kasami M. Treatment strategy for cutaneous apocrine carcinoma. Int J Clin Oncol. 2014;19(4):712\u20135. https:\/\/doi.org\/10.1007\/s10147-013-0594-x.","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"4892_CR6","doi-asserted-by":"publisher","first-page":"3472","DOI":"10.1002\/ccr3.3434","volume":"8","author":"F Collette","year":"2020","unstructured":"Collette F, Hamoir M, Van Eeckhout P, et al. Metastatic cutaneous apocrine adenocarcinoma successfully treated with systemic anti-androgen therapy-A case report. Clin Case Rep. 2020;8(12):3472\u20138. https:\/\/doi.org\/10.1002\/ccr3.3434.","journal-title":"Clin Case Rep"},{"issue":"6","key":"4892_CR7","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000028808","volume":"101","author":"JH Choi","year":"2022","unstructured":"Choi JH, Oh HM, Kim KS, et al. Primary cutaneous apocrine carcinoma of the scalp: two case reports and literature review. Medicine (Baltimore). 2022;101(6):e28808. https:\/\/doi.org\/10.1097\/md.0000000000028808.","journal-title":"Medicine (Baltimore)"},{"key":"4892_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijscr.2024.109513","volume":"117","author":"N Khessairi","year":"2024","unstructured":"Khessairi N, Fertani Y, Sakhri S, et al. Primary cutaneous apocrine carcinoma: a challenging case report. Int J Surg Case Rep. 2024;117:109513. https:\/\/doi.org\/10.1016\/j.ijscr.2024.109513.","journal-title":"Int J Surg Case Rep"},{"issue":"4","key":"4892_CR9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1002\/jso.22023","volume":"105","author":"KL Hollowell","year":"2012","unstructured":"Hollowell KL, Agle SC, Zervos EE, Fitzgerald TL. Cutaneous apocrine adenocarcinoma: defining epidemiology, outcomes, and optimal therapy for a rare neoplasm. J Surg Oncol. 2012;105(4):415\u20139. https:\/\/doi.org\/10.1002\/jso.22023.","journal-title":"J Surg Oncol"},{"issue":"5","key":"4892_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.5021\/ad.2016.28.5.669","volume":"28","author":"SH Loh","year":"2016","unstructured":"Loh SH, Oh YJ, Lew BL, Sim WY. Primary cutaneous apocrine carcinoma. Ann Dermatol. 2016;28(5):669\u201370. https:\/\/doi.org\/10.5021\/ad.2016.28.5.669.","journal-title":"Ann Dermatol"},{"issue":"4","key":"4892_CR11","doi-asserted-by":"publisher","first-page":"253","DOI":"10.5021\/ad.1996.8.4.253","volume":"8","author":"I-S Jun","year":"2016","unstructured":"Jun I-S, Haw C-R, Kim N-I. Apocrine gland carcinoma. ad. 2016;8(4):253\u20136. https:\/\/doi.org\/10.5021\/ad.1996.8.4.253.","journal-title":"ad"},{"issue":"1","key":"4892_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/modpathol.3800007","volume":"17","author":"KM Hiatt","year":"2004","unstructured":"Hiatt KM, Pillow JL, Smoller BR. Her-2 expression in cutaneous eccrine and apocrine neoplasms. Mod Pathol. 2004;17(1):28\u201332. https:\/\/doi.org\/10.1038\/modpathol.3800007.","journal-title":"Mod Pathol"},{"issue":"12","key":"4892_CR13","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1007\/s10147-023-02420-z","volume":"28","author":"S Tsuruta","year":"2023","unstructured":"Tsuruta S, Ogata D, Namikawa K, et al. Prognostic factors in cutaneous apocrine carcinoma: a single-institution retrospective study of 32 patients. Int J Clin Oncol. 2023;28(12):1690\u20136. https:\/\/doi.org\/10.1007\/s10147-023-02420-z.","journal-title":"Int J Clin Oncol"},{"issue":"10","key":"4892_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047290","volume":"7","author":"LP Le","year":"2012","unstructured":"Le LP, Dias-Santagata D, Pawlak AC, et al. Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS ONE. 2012;7(10):e47290. https:\/\/doi.org\/10.1371\/journal.pone.0047290.","journal-title":"PLoS ONE"},{"issue":"3","key":"4892_CR15","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1159\/000510097","volume":"13","author":"M Libertini","year":"2020","unstructured":"Libertini M, Oneda E, Di Biasi B, Savelli G, Zaniboni A. Cutaneous adnexal carcinoma with apocrine differentiation: a challenging diagnosis and personalized treatment with mTOR inhibitor in a very rare disease. Case Rep Oncol. 2020;13(3):1091\u20136. https:\/\/doi.org\/10.1159\/000510097.","journal-title":"Case Rep Oncol"},{"key":"4892_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.ejca.2017.11.008","volume":"90","author":"M Rogatsch","year":"2018","unstructured":"Rogatsch M, Schmid J, Lax S, et al. Metastatic cutaneous apocrine adenocarcinoma responsive to the programmed cell death protein 1 inhibitor pembrolizumab. Eur J Cancer. 2018;90:146\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2017.11.008.","journal-title":"Eur J Cancer"},{"issue":"1","key":"4892_CR17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1001\/jamadermatol.2015.2507","volume":"152","author":"M Otsuka","year":"2016","unstructured":"Otsuka M, Yamasaki O, Kaji T, Shien T, Iwatsuki K. Metastatic cutaneous apocrine adenocarcinoma treated with a combination of pertuzumab-based targeted therapy and taxane chemotherapy: a case report. JAMA Dermatol. 2016;152(1):111\u20133. https:\/\/doi.org\/10.1001\/jamadermatol.2015.2507.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"4892_CR18","doi-asserted-by":"publisher","first-page":"654","DOI":"10.2340\/00015555-1354","volume":"92","author":"T Hidaka","year":"2012","unstructured":"Hidaka T, Fujimura T, Watabe A, et al. Successful treatment of HER-2-positive metastatic apocrine carcinoma of the skin with lapatinib and capecitabine. Acta Derm Venereol. 2012;92(6):654\u20135. https:\/\/doi.org\/10.2340\/00015555-1354.","journal-title":"Acta Derm Venereol"},{"key":"4892_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11061607","author":"T Hu","year":"2022","unstructured":"Hu T, Liu Y, Wu J, et al. Triple-negative apocrine breast carcinoma has better prognosis despite poor response to neoadjuvant chemotherapy. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11061607.","journal-title":"J Clin Med"},{"issue":"16","key":"4892_CR20","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","volume":"389","author":"SJ Freedland","year":"2023","unstructured":"Freedland SJ, de Almeida Luz M, De Giorgi U, et al. Improved outcomes with enzalutamide in biochemically recurrent prostate cancer. N Engl J Med. 2023;389(16):1453\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2303974.","journal-title":"N Engl J Med"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04892-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:07:17Z","timestamp":1775552837000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04892-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4892"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04892-7","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cEthical approval for publication of this case report was waived by the Institutional Review Board of the University Hospital Hradec Kr\u00e1lov\u00e9, as individual case reports do not require formal ethical review.\u201d Patient signed informed consent with the provided therapy and participation in the treatment, as required by law in the Czech Republic.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for submission and publication of the case report and related images was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"534"}}